ArticleClinical Medicine Insights. Oncology2016
Cytokines and Prognostic Factors in Epithelial Ovarian Cancer.
Article in Clinical Medicine Insights. Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients.Frontiers in immunology · 2024Article
- Studies on the Role of Compartmentalized Profiles of Cytokines in the Risk of Hepatocellular Carcinoma.International journal of molecular sciences · 2023Article
- Immunostaining of stromal CD56 cells in ovarian malignancies.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Periostin promotes ovarian cancer metastasis by enhancing M2 macrophages and cancer-associated fibroblasts via integrin-mediated NF-κB and TGF-β2 signaling.Journal of biomedical science · 2022Article
- Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer.BMC cancer · 2021Article
- The Cancer Stem Cell Niche in Ovarian Cancer and Its Impact on Immune Surveillance.International journal of molecular sciences · 2021Review
- Comorbidities and inflammation associated with ovarian cancer and its influence on SARS-CoV-2 infection.Journal of ovarian research · 2021Review
- A high-performance microfluidic detection platform to conduct a novel multiple-biomarker panel for ovarian cancer screening.RSC advances · 2021Article
- IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.Advances in experimental medicine and biology · 2021Review
- Association between interleukin-32 polymorphisms and ovarian cancer in the Chinese Han population.International journal of clinical and experimental pathology · 2020Article
- KCNH3 Predicts Poor Prognosis and Promotes Progression in Ovarian Cancer.OncoTargets and therapy · 2020Article
- Stromal IL2 is related to the neutrophil/lymphocyte ratio in epithelial ovarian cancer.Pathologica · 2019Article
- Cytokines secreted by human Wharton's jelly stem cells inhibit the proliferation of ovarian cancer (OVCAR3) cellsOncology letters · 2019Article
- Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities.Cancer medicine · 2018Review
- Role of tumor microenvironment in ovarian cancer pathobiology.Oncotarget · 2018Review
- Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach.Journal of translational medicine · 2018Article
- Genetic Association of Interleukin-31 Gene Polymorphisms with Epithelial Ovarian Cancer in Chinese Population.Disease markers · 2018Article
- The Crosstalk between Ovarian Cancer Stem Cell Niche and the Tumor Microenvironment.Stem cells international · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOvarian cancer has a high mortality and delayed diagnosis. Inflammation is a risk factor for ovarian cancer, and the inflammatory response is involved in almost all stages of tumor development. Immunohistochemical staining in stroma and epithelium of a panel of cytokines in benign and malignant ovarian neoplasm was evaluated. In addition, immunostaining was related to prognostic factors in malignant tumors.
methodThe study group comprised 28 ovarian benign neoplasias and 28 ovarian malignant neoplasms. A panel of cytokines was evaluated by immunohistochemistry (Th1: IL-2 and IL-8; Th2: IL-5, IL-6, and IL-10; and TNFR1). Chi-square test with Yates' correction was used, which was considered significant if less than 0.05.
resultsTNFR1, IL-5, and IL-10 had more frequent immunostaining 2/3 in benign neoplasms compared with malignant tumors. Malignant tumors had more frequent immunostaining 2/3 for IL-2 in relation to benign tumors. The immunostaining 0/1 of IL 8 was more frequent in the stroma of benign neoplasms compared with malignant neoplasms. Evaluation of the ovarian cancer stroma showed that histological grade 3 was significantly correlated with staining 2/3 for IL-2 (P = 0.004). Women whose disease-free survival was less than 2.5 years had TNFR1 stromal staining 2/3 (P = 0.03) more frequently.
conclusionIL-2 and TNFR1 stromal immunostaining are related prognostic factors in ovarian cancer and can be the target of new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.